Company Encyclopedia
View More
name
CANBRIDGE-B
01228.HK
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy.
1.324 T
01228.HKMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking47/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE39.49%A
    • Profit Margin-217.58%E
    • Gross Margin69.31%A
  • Growth ScoreD
    • Revenue YoY-40.11%E
    • Net Profit YoY66.58%A
    • Total Assets YoY-56.83%E
    • Net Assets YoY-48.69%E
  • Cash ScoreE
    • Cash Flow Margin-45.96%D
    • OCF YoY-40.11%E
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreE
    • Gearing Ratio487.75%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Hong Kong stock market's pharmaceutical and biotechnology sector leads in gains

    On October 27th, the Hong Kong stock market saw significant gains in the pharmaceuticals and biotechnology sector. XUANZHUBIO-B rose nearly 19%, CANBRIDGE-B increased over 14%, SINOMAB BIO-B climbed over 11%, BAIOO SAI TU-B and HUAKANG BIOMED both surged over 9%, and JW THERAP-B rose over 8%

    Zhitong·
    HK
    02575
    -0.63%
    HK
    01228
    -4.95%
    HK
    03681
    -3.01%
    Zhitong·
    HK
    02575
    -0.63%
    HK
    01228
    -4.95%
    HK
    03681
    -3.01%

    CANBRIDGE-B completed the issuance of 9.996 million shares, raising approximately HKD 22.5914 million

    According to the announcement from CANBRIDGE-B, the conditions specified in the subscription agreement have been met, and the delivery of the subscription matter was implemented on September 26, 2025, in accordance with the terms and conditions of the subscription agreement. On the delivery date, the company allocated and issued a total of 9.996 million subscription shares to the subscribers at a subscription price of HKD 2.26 per share, as stated in the announcement. The total amount raised from the subscription matter is HKD 22.5914 million

    Zhitong·
    HK
    01228
    -4.95%
    Zhitong·
    HK
    01228
    -4.95%

    Understanding the Market | CANBRIDGE-B rose over 8% in the morning, plans to issue subscription shares at a discount of approximately 19.86% to raise funds for existing product line R&D expenses, etc

    CANBRIDGE-B rose over 8% in the morning, and as of the time of publication, it was up 8.16%, trading at HKD 3.05, with a transaction volume of HKD 20.5877 million. In terms of news, CANBRIDGE-B announced that on September 15, 2025, the company plans to issue a total of 9.9962 million subscription shares to three subscribers (Qin Shen, Huang Xiaoting, and Wusong Capital Limited). The subscription price for each share is HKD 2.26, which represents a discount of approximately 19.86% compared to the closing price of HKD 2.82 on September 15. The announcement stated that the total amount raised from the subscription will be HKD 22.5914 million, with the net proceeds estimated to be approximately HKD 22.0914 million. The company intends to use the net proceeds from the subscription for research and development expenses of existing product lines and for the group's daily operations

    Zhitong·
    HK
    01228
    -4.95%
    Zhitong·
    HK
    01228
    -4.95%

    CANBRIDGE-B plans to issue 9,996,200 shares at a discount of approximately 19.86%, raising about HKD 22,091,400 net

    CANBRIDGE-B plans to issue 9.9962 million shares to 3 subscribers on September 15, 2025, with a subscription price of HKD 2.26 per share, representing a discount of approximately 19.86% to the closing price. This subscription is expected to raise HKD 22.5914 million, with a net amount of approximately HKD 22.0914 million, primarily for research and development expenses and daily operations

    Zhitong·
    HK
    01228
    -4.95%
    Zhitong·
    HK
    01228
    -4.95%

    CANBRIDGE-B is issuing new shares at a discount of 19.86%, raising a net amount of 22.09 million yuan

    CANBRIDGE-B announced that it will issue a total of 9.9961 million new shares to three independent third parties, equivalent to an enlarged share capital of 1.96%; the price per share is HKD 2.26, representing a discount of 19.86% compared to the last trading day (15th). The total amount raised is HKD 22.59 million, with a net amount of HKD 22.09 million, intended for research and development expenses for existing product lines and daily operations

    AASTOCKS·
    HK
    01228
    -4.95%
    AASTOCKS·
    HK
    01228
    -4.95%
    Posts
    View More